Abstract: A method for producing a porous metallic structure comprising a metal element from a metal salt comprising a cation part and an anion part, comprising the steps of: providing a volume of metal salt; exposing the volume of metal salt in an atmosphere comprising a reduction gas at a temperature below a melting temperature of the metal element, leading to converting the volume of metal salt into the porous metallic structure by removing the anion part using the reduction gas; wherein the porous metallic structure has a pore size between 1 nanometer and 50 micrometer, and a ligament size between 1 nanometer and 50 micrometer; wherein the ligament size is controlled by the temperature during the exposing.

Abstract: The invention relates to the use of phosphopantetheine compounds alone and in combination with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Preferred medical uses relate to the treatment or prevention of dyslipidemia.

Abstract: The invention is directed to a method and a surgical instrument, typically a surgical stapler that is configured for performing anastomosis of a first gastro-intestinal tract section to a second gastro-intestinal tract section, both gastro-intestinal tract sections comprising a superficial layer and an intermediate layer. Said method comprises contacting the superficial layers of said gastro-intestinal tract sections and compressing the contacted sections between a first pressure area and a second pressure area, wherein the sum of the first pressure area and the second pressure increases during the compression such that the superficial layers are pressed aside and the intermediate layers are contacted.

Abstract: A breath actuated dry powder inhaler with a single air circulation chamber for de-agglomeration of entrained powdered medicament using the energy of the inspiratory air stream. The chamber has a substantially polygonal sidewall, a plurality of air supply channels entering the chamber substantially tangentially to its sidewall. A powder channel extends through a powder dose supply region of the inhaler tangentially into the chamber. An air outlet axially extends from a discharge and connects to a discharge channel that extends to a mouthpiece. The polygonal sidewall comprises at least six straight line segments, each straight line segments being spaced at the same first distance from an adjacent one forming the plurality of air supply channels. The air supply channels have the same width. The powder channel is defined by two straight line segments which are spaced from each other at a second distance which is larger than the first distance.

Abstract: A prosthetic heart valve having a pair of cooperating leaflets mounted in a valve body to alternate between an open position where the flow of blood in a downstream direction is permitted and a closed position where the flow of blood in the reverse direction is counteracted. Pivot member sets at diametrically opposite sides of each leaflet guide the leaflets moving between the open and closed positions, each set including an ear or a recess cooperating with an associated cavity or knob of an interior surface of the valve body. Each ear or recess bounds at least one leaflet passageway through that ear or recess and located spaced from upstream and downstream ends of the ear for allowing flow through that ear and the associated cavity, or through that recess, when the leaflets are in the closed positions.

Abstract: The present invention provides novel compounds of formula (I) that are useful as inhibitors of the PD-1/PD-L1 protein/protein interaction.

Abstract: The present invention relates to new biomarkers and new sets of biomarkers for diagnosing a mood disorder, preferably depression or monitoring the effectiveness of therapy for said mood disorder.

Abstract: The present invention relates to compositions which may comprise a molecular sled linked to cargo and uses thereof. In particular, the present invention relates to a non-naturally occurring or engineered composition which may comprise a molecular sled, linkers and a molecular cargo connected to the sled via the linkers. Methods involving the use of molecular sleds and their cargoes and pharmaceutical compositions, methods for treating cancer, a degenerative disease, a genetic disease or an infectious disease as well as diagnostic methods are also contemplated by the present invention.

Abstract: The invention relates to (S)-acyl-4?-phosphopantetheine derivatives, methods of their synthesis, and related medical uses of such compounds. Preferred medical uses relate to the treatment of neurodegenerative diseases, such as PKAN.

Abstract: The invention relates to extracting kinetic energy from surface waves. Therein, at least one float (8) is kept floating in the area of the surface waves, while a working fluid is held in a reservoir structure (2, 3). The float is connected to a fluid displacement structure in such manner that an individual surface wave, which causes an upward stroke of the float, moves the working fluid within the reservoir structure in such manner that the potential energy of the working fluid is increased. Before the wave has reached the float, the wave is detected by a sensor (7). Based on said detection, a prediction is calculated of the amount of kinetic energy available in the wave. Tuned to said prediction, an energy transmission structure of the fluid displacement structure is adjusted for realizing the energy conversion.

Abstract: The invention relates to drug development and synthetic chemistry, in particular to the manufacture of biologically active compounds based on naturally occurring molecules. It also relates to novel biologically active compounds, for example aminoglycoside antibiotics, in a substantially pure regioisomeric form. More particularly, the present invention relates to methods for the chemo- or regioselective derivatization of a target compound with multiple reactive groups, some of which may be derivatezed, and other which will not be derivatized.

Abstract: The invention relates to the field of immunology and vaccine development. In particular, it relates to antibodies and fragments thereof against Staphylococcus aureus and to therapeutic and diagnostic uses thereof. Provided is an isolated antibody or a functional fragment thereof, which binds to an epitope of the Immunodominant Staphylococcal antigen A (IsaA), wherein said antibody comprises at least four Isa A epitope-binding CDR sequences selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6, and functional equivalents thereof having an amino acid sequence that is at least 85% identical to an amino acid sequence of SEQ ID NO: 1-6.

Abstract: The invention relates to the field of carbohydrate chemistry. Provided is a process for the regioselective oxidation of a single secondary hydroxy function of a carbohydrate substrate comprising two or more secondary hydroxy functions, comprising contacting the carbohydrate substrate in a solvent in the presence of a transition metal catalyst complex with an oxidizing agent to yield a mono-oxidized carbohydrate.

Abstract: The invention relates to methods, reagents and kits for detecting the susceptibility to cervical cancer. In particular, it relates to novel methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3 (CIN2/3) and the use thereof for identifying a cervical cell as neoplastic or predisposed to neoplasia in an isolated sample.

Abstract: The invention relates to novel therapeutic compounds, more in particular to biologically active analogs and uses thereof as medicament, for instance for the treatment of atrial fibrillation. Provided is a compound of the general formula (formula I) wherein R1 is H or a saturated or unsaturated aliphatic moiety comprising 1 to 8 C-atoms; and X is selected from the group consisting of moieties X1, X2, X3, X4, X5 and X6. Exemplary uses include the prevention or therapeutic treatment of a HSF1-mediated disease.

Abstract: The invention relates to the field of poly-and oligosaccharides and their nutritional effects. In particular, it relates to the application of ?-glucanotransferases in methods for preparing dietary fibers, including prebiotic oligosaccharides, and to novel oligosaccharides obtainable thereby. Provided is a method for producing a mixture of gluco-oligosaccharides having one or more consecutive (?1?6) glucosidic linkages and one or more consecutive (?1?4) glucosidic linkages, comprising contacting a poly- and/or oligosaccharide substrate comprising at least two (?1?4) linked D-glucose units with an ?-glucanotransferase capable of cleaving (?1?4) glucosidic linkages and making new (?1?4) and (?1?6) glucosidic linkages. Also provided are (isolated) gluco-oligosaccharides obtainable thereby, and their application in nutritional and cosmetic compositions.

Abstract: The invention relates to a method for providing analogs of human milk oligosaccharides (HMO), in particular oligosaccharides containing terminal sialic acid. The method comprises the steps of: a) providing a source of non-digestible galactooligosaccharides (GOS) containing at least two terminally bonded ?-linked galactose residues; b) providing a sialic acid donor having (?2-3)-sialylated O-glycans; c) contacting said GOS with said sialic acid donor in the presence of an enzyme having trans-sialidase activity in an enzyme reaction mixture; and d) isolating from said enzyme reaction mixture a fraction comprising at least 20 percent by weight of disialylated galactooligosaccharides (di-Sia-GOS) based on the dry matter.

Abstract: The invention relates to a method for providing analogs of human milk oligosaccharides (HMO), in particular oligosaccharides containing terminal sialic acid. The method comprises the steps of: a) providing a source of non-digestible galactooligosaccharides (GOS) containing at least two terminally bonded ?-linked galactose residues; b) providing a sialic acid donor having (?2-3)-sialylated O-glycans; c) contacting said GOS with said sialic acid donor in the presence of an enzyme having trans-sialidase activity in an enzyme reaction mixture; and d) isolating from said enzyme reaction mixture a fraction comprising at least 20 percent by weight of disialylated galactooligosaccharides (di-Sia-GOS) based on the dry matter.

Abstract: The present invention relates to the use of ?-glucan branching enzymes in transglycosylation reactions.

Abstract: The invention relates to extracting kinetic energy from surface waves. Therein, at least one float (8) is kept floating in the area of the surface waves, while a working fluid is held in a reservoir structure (2, 3). The float is connected to a fluid displacement structure in such manner that an individual surface wave, which causes an upward stroke of the float, moves the working fluid within the reservoir structure in such manner that the potential energy of the working fluid is increased. Before the wave has reached the float, the wave is detected by a sensor (7). Based on said detection, a prediction is calculated of the amount of kinetic energy available in the wave. Tuned to said prediction, an energy transmission structure of the fluid displacement structure is adjusted for realizing the energy conversion.